Quizartinib

Inhibitor of FLT3 and ABC proteins

Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in Phase II clinical trials. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 μM , respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Recently, AC220 has also been shown to be an effective inhibitor of ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 μM and from 0.5 to 10 μM , respectively, and inhibited [125I]-IAAP photolabeling of ABCG2 and ABCB1 with IC $_{50}$ values of 0.07 and 3.3 μM , respectively.

Citations: 1

View Online »


Ordering Information

Order Online »

ENZ-CHM154-0001	1mg
ENZ-CHM154-0005	5mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Short Term Storage +4°C

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name AC-220, 1-(5-tert-Butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-

b][1,3]benzothiazol-2-yl]phenyl]urea

Appearance White powder.

CAS 950769-58-1

Couple Target BCRP, Flt, P-glycoprotein

Couple Type Inhibitor

Formula $C_{29}H_{32}N_6O_4S$

Identity Determined by EM-MS, NMR

MW 560.7

Purity ≥97% (HPLC)

Soluble in DMSO (33mg/ml) or ethanol (0.5mg/ml).

